The company’s mixed quarterly results and uninspiring guidance led to a sell-off.
The stock of Baxter International (BAX 14.50%), a specialist of long standing in the medical device and associated products space, could have used a little pick-me-up on Thursday. The company posted a mixed third quarter that missed on analyst profitability estimates. An unforgiving market sent its share price down by almost 15% that trading session alone.
Two metrics going in the opposite direction
Before market open, Baxter published those quarterly figures. They revealed that total sales rose 5% year over year to $2.84 billion, while net income not according to generally accepted accounting principles (GAAP) sank by 14% to $355 million ($0.69 per share).
Image source: Getty Images.
Funnily enough, the improved revenue figure was below the consensus analyst estimate of $2.88 billion, but the shrunken non-GAAP (adjusted) net profit beat the $0.60 projection.
Baxter divides its business into three segments, two of which posted net sales growth during the quarter. Pharmaceuticals led the way with a 7% gain, to $632 million, while healthcare systems and technologies rose by 3% to $773 million. On the other hand, medical products and therapies declined by 1% to slightly under $1.33 billion. The “other” category rose more than fivefold to $101 million.
Today’s Change
(-14.50%) $-3.25
Current Price
$19.17
Key Data Points
Market Cap
$12B
Day’s Range
$18.47 – $19.80
52wk Range
$18.47 – $37.74
Volume
1.4M
Avg Vol
7.5M
Gross Margin
35.46%
Dividend Yield
0.03%
Guidance comes up short
Another factor bringing the bears to Baxter stock Thursday was its guidance. For the full year, management is now anticipating sales growth of 1% to 2% over the 2024 result. Adjusted net income for the period is forecast at $2.35 to $2.40 per share, below the average analyst estimate of $2.44.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.